By targeting both interleukin (IL)-12 and IL-23, Stelara is the first therapeutic that aims to stop T helper cells from producing interleukin (IL)-17 and other cytokines, which have been ...

The decision to start the ICONIC-ASCEND study of icotrokinra versus IL-12 and IL-23 inhibitor Stelara (ustekinumab) comes on the back of the placebo-controlled phase 3 ICONIC-LEAD study ...

Celltrion is introducing Steqeymaq (ustekinumab-stba), which is a biosimilar to Johnson & Johnson's Stelara (ustekinumab ... beyond TNF-alpha to include IL-12/23 inhibitors, offering more ...

It will compete with other biologic therapies for Crohn's, including J&J's IL-12 and IL-23 inhibitor Stelara (ustekinumab), Takeda's Entyvio (vedolizumab) and Biogen's Tysabri (natalizumab ...

STEQEYMA®, formerly known as CT-P43, is a human IL-12 and -23 antagonist indicated for multiple immune-mediated diseases. It encompasses all indications approved for the STELARA® reference ...

while AbbVie’s Skyrizi hit the scene as the first IL-23 med cleared by the FDA to treat Crohn’s in mid-2022. Much like with Tremfya and Stelara, AbbVie has pinned its hopes on Skyrizi to fill ...

The FDA has also provisionally determined that SELARSDI will be interchangeable with Stelara upon the expiration ... a component common to both interleukin (IL)-12 and IL-23 cytokines, which ...

JERSEY CITY, N.J., March 27, 2025 /PRNewswire/ -- Celltrion, Inc., today announced that STEQEYMA ® (ustekinumab-stba), a biosimilar to STELARA ® (ustekinumab) has been added to the Costco Member ...

STEQEYMA®, formerly known as CT-P43, is a human IL-12 and -23 antagonist indicated for multiple immune-mediated diseases. It encompasses all indications approved for the STELARA® ...